


# PLASFER SRL



*May 11<sup>th</sup>, 2021*

**Company Presentation**



## **FORWARD-LOOKING STATEMENT**

*This presentation may contain forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective product candidates, planned clinical trials and preclinical activities, including timing related to such trials and expected results, research and development costs, current and prospective collaborations; the estimated size of the market for our product candidates, the timing and success of our development and commercialization of our anticipated product candidates; and the availability of alternative therapies for our target market. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.*

*Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Plasfer srl recommends that investors independently evaluate specific investments and strategies.*

*This presentation may contain tradenames, trademarks or service marks of other companies. Plasfer srl does not intend the use or display of other parties' tradenames, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, these other parties.*



PLASFER SRL

"Cure with Platelets"



# COMPANY BACKGROUND

*Mission: use platelets and platelet-derived microparticles for drug-delivery and cell therapy applications*

=> Privately held; founded in 2015 in Perugia (Italy) as a spin-off at the University of Perugia.

=> Wholly-owned PTT™ (Platelets Transfer Technology) platform allows to use engineered platelets in gene/cell therapies and drug-delivery applications.

=> **Established strategic Collaborations/Partnerships:**

- University of Perugia - Spin-off agreement
- Amsterdam UMC - Cancer Center
- CRO Aviano

=> **Funding to date**

- Founders & Friends
- National competition: StartCup2015– BioInItaly2016 – Unicredit Startlab 2020
- EU competition: Novartis Oncology Award 2016
- Seed-round: private investor 2020



PLASFER SRL

# Technology Platform Introduction

Overview of our technology platform




# OUR TECHNOLOGY


## *Platelets Transfer Technology (PTT™)*



Nucleic Acids



Small Molecules







Protein/Antibodies

Plasfer PTT™ is a proprietary and patented technology platform able to load/engineer platelets at high efficiency with an array of different molecular entities without altering their natural morphology and functionality.

= EU-Patent Granted 2020 (EP 2951292) = US-Patent Pending-2021 (US 20150361453)



# PLATELET-BASED CELL THERAPY



**Platelets are  
a Natural  
and Safe  
Delivery  
Vehicles**

**Highly  
Scalable  
Production**




**Broad  
Therapeutic  
Indications**

**History  
of  
Transfusion**

**Tolerability**



# PTT™ DISTINCTIVE FEATURES



**High  
Efficiency of  
Loading**

**Proprietary  
and  
patented**

**High number  
(300M/ml of  
blood)**

**Fast  
transfection**

**Autologous &  
Allogeneic  
Application**



# PTT™ COMPETITIVE ADVANTAGE

*Platelets vs. Other cell-based therapy technologies*

	Cellular platform for drug delivery	Vascular circulation	Lack of nucleus as advantage	Natural targeting selectivity for inflammation/wounds/tumors
Stem cells	X	X		
Red blood cells	X	X	X	
Exosomes	X	X	X	
Platelets	X	X	X	X



PLASFER SRL

# Technology Platform Validation

Plasfer's PTT™ Technology Platform Validation



# Platelets Transfer Technology (PTT™)

*Platelets have a unique potential as therapeutics delivery vehicle – Plasfer is the only company engineering platelets isolated from whole blood with an array of therapeutic molecules*

- => Both autologous and allogeneic (blood bank) human platelets can be used.
- => Platelets have high affinity for circulating tumor cells and can be used to specifically target metastasizing cells.
- => Engineered platelets concentrate, get in contact and are activated by the tumor, thus enhancing the release of their engineered payload.
- => Platelets protect genetic materials from extracellular degradation.



# PLASFER Therapeutic Areas

- **PLA-GBM™ Program**

*Platelet-mediated delivery of RNAi (siRNA-miRNA) for the treatment of Glioblastoma R/R (IDH-wildtype IV grade glioma) after surgical removal.*

- **PLA-ONCO™ Program**


*Platelet-mediated delivery of siRNA for the treatment of Solid Tumors, i.e., Pancreatic, Lung and Melanoma*

- **PLA-VAX™ Program**

*Platelets as engineered antigen-presenting cells for vaccine development, e.g., Influenza, Covid-19 and Cancer (PTT™ Emerging application)*


- **PLA-REGEN™ Program**

*Platelets rich plasma (PRP), engineered for regenerative medicine applications (PTT™ Emerging application)*



# CURRENT PIPELINE

Cancer



R/R Glioblastoma

Tumors



PLASFER SRL

# Team & Facilities

Meet the Team and State of the Art Facilities

## MANAGEMENT TEAM



**Marco Malvestiti, PhD: Founder & Chief Executive Officer.** *Double Ph.D. from the University of Perugia-Italy. He founded his first start-up company “SocialPiù srl” in 2011 operating in the Social Media Marketing field. He worked for the company as manager, and successfully exited in 2014.*



**Rosario Billella, D.Sc: Chief Operating Officer.** *Former executive officer at Abilita Bio, Kai BioEnergy, Androclus Therapeutics. Former Professor at the University of Chile and UC, San Diego. Biotechnology professional and Immunologist with a deep understanding of drug discovery & development and early-stage company operations.*



**Paolo Gresele, M.D.,Ph. D.: Chief Scientific Officer.** *Degree in Medical Sciences at University of Leuven (Belgium). He is full professor of Internal Medicine at University of Perugia. Internationally recognized expert of platelet biology and physiology. Authors of more than 200 scientific peer-reviewed articles, he is vice president and future president of Italian Society of Hemostasis and Thrombosis (SISET).*



## FACILITIES & OPERATIONS

*The company has access to a dedicated and fully equipped laboratory and administrative facilities as well as a state-of-the-art animal facility through a “spin-off” agreement with the Faculty of Medicine at the University of Perugia, ITALY.*

## TEAM MEMBERS

*Plasfer’s research team includes scientists and technicians with a wide skillset that includes Molecular Biology; Cell culture; Animal models; Statistics.*

## IP COUNSELORS

- EU: Barzano’ & Zanardo. Milan, ITALY
- US: Salvadori-Law, New York, NY, USA




## IT & MEDIA

**Alessandro Caprai, Head of IT & Media consulting group.** *Provides his IT and media expertise and marketing services.*

## BORD OF DIRECTORS



**Marco Malvestiti, PhD: CEO. & Director.** *M.S. in Industrial Biotechnology at the University of Perugia (Italy) in 2008. He obtained two Ph.D.s at the University of Perugia (Italy). He founded his first start-up company “SocialPiù srl” in 2011 operating in the Social Media Marketing field, the first social media agency in Italy. He worked for the company as manager, and successfully exited in 2014.*



**Paolo Gresele, M.D.,Ph. D.: Chief Scientific Officer & Director.** *Degree in Medical Sciences at University of Leuven (Belgium) 1987. He is full professor in Internal Medicine at University of Perugia. He is an internationally recognized expert of platelet biology and physiology. Authors of more than 200 scientific peer-reviewed articles, he is vice president and future president of Italian Society of Hemostasis and Thrombosis (SISSET).*



**Giacomo Rimatori, J.D: Corporate Consul & Director.** *Corporate and business attorney with training experiences in San Francisco, CA, United States, where he attended the MTB startup school and in London, UK. He mainly works for startup and IT companies. He is also a privacy specialist and DPO. He sits on the board of advisors and in the statutory board of several companies*



**Luigi De Marco, M.D.,: Chief Technology Officer & Director.** *Former Director of the Department of Advanced Cell Therapies at Center National Cancer Institute (CRO) until 2013. Now, he is a consultant for the same center. Adjunct Professor at Department of Molecular and Experimental Medicine in Scripps Research Institute La Jolla, San Diego County, California (USA). He is an expert of transfusion medicine and has great contacts with the pharmaceuticals companies and universities that will be helping for the project development.*



**Zaverio Ruggeri, M.D.,: Director.** *Internationally recognized leader in platelet research. He is a Professor at SCRIPPS-La Jolla, CA and Founder of MeruVasimmune-San Diego, CA. He has authored more than 200 peer-reviewed papers and characterized key molecules and mechanisms in platelet biology. Dr. Ruggeri has consulted for and developed numerous research and business collaborations with multiple pharmaceutical companies.*



PLASFER SRL

EMAIL ADDRESS

[info@plasfer.bio](mailto:info@plasfer.bio)

PHONE NUMBER

+39 339 316 4455

CORPORATE ADDRESS

Via Cacciatori delle Alpi,28  
Perugia, Italy

Contact Us: Be part of the next Cell-  
Therapy Revolution